Strand Life Sciences partners with Mazumdar-Shaw Medical Foundation

With the aim of making genomics-based diagnostics accessible and affordable for people in India, Strand Life Sciences has partnered with Mazumdar-Shaw Medical Foundation


Strand, a global life sciences & clinical genomics company headquartered in Bangalore, entered into a partnership with the Mazumdar-Shaw Medical Foundation (MSMF) to set up the Strand at Mazumdar-Shaw (SAMS) translational lab in the Mazumdar-Shaw Centre for Translational Research (MSCTR) in Bangalore.

This is a major milestone towards enabling an ecosystem of personalized medical treatment for patients with cancer and other genetic diseases.

"It gives us great pleasure to partner with Strand Life Sciences, a pioneer in genomics and personalized medicine. With evolving healthcare systems, it is imperative that we are constantly innovating and developing capabilities that will provide personalized treatment and quality care to the people of India. We believe this collaboration will help us foster innovation and encourage in-depth research in the genomics space and thereby provide better care for patients with cancer and other genetic diseases," said Dr Kiran Mazumdar-Shaw, CMD, Biocon.

Based on statistics, nearly seven lakh Indians die of cancer every year, while over 10 lakh are newly diagnosed with some form of the disease.

According to the latest World Cancer Report from the World Health Organization (WHO), there are over 4.77 lakh men and 5.37 lakh women diagnosed with cancer in India in 2012 alone. The scale of these challenges requires the Indian healthcare industry to use affordability as a driver of innovation.

Strand through its expertise will offer comprehensive genomic testing for cancer and other germline or hereditary conditions at highly affordable costs.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email